Biolinq Shine Review: Accuracy, Cost, and Wear Time
The Biolinq Shine is a 7-day real-time cgm continuous glucose monitor with a 0% MARD accuracy rating. Biolinq Shine is a next-generation on-skin CGM biosensor in development that aims to eliminate needle insertion entirely. Using a proprietary electrochemical array applied directly to the skin surface, it represents a fundamentally different approach to glucose sensing. The product is in clinical trials with no confirmed FDA clearance date or commercial launch timeline.
The Biolinq Shine is available over the counter without a prescription, making it accessible to anyone 18 and older who wants to monitor their glucose patterns. At N/A — not yet commercially available, it is purchased directly by consumers and is not covered by insurance or Medicare. This device is designed for wellness monitoring, metabolic health optimization, and prediabetes awareness — not for managing insulin-dependent diabetes or making insulin dosing decisions.
Released in 2025 by Emerging CGM Manufacturers (Various), the Biolinq Shine uses electrochemical biosensor (on-skin, minimally invasive) technology to measure glucose in interstitial fluid. It is factory-calibrated and requires no fingerstick confirmations during use. The warmup period after sensor insertion is 0 minutes, one of the fastest in the CGM market.
Biolinq Shine
by Emerging Brands
Key Specifications
| Product | MARD | Wear Time | Type | Rx? | With Insurance | Without Insurance | Medicare | Rating |
|---|---|---|---|---|---|---|---|---|
| Biolinq Shine | 0% | 7 days | Real time CGM | No | N/A — not yet commercially available | N/A — not yet commercially available | — |
Sensor Type
Electrochemical biosensor (on-skin, minimally invasive)
Water Resistance
TBD — product in development
Age Approval
TBD — not yet FDA-cleared
Transmitter Life
Integrated (projected)
How Accurate Is the Biolinq Shine?
The Biolinq Shine does not yet have published MARD data from completed pivotal trials. This product is still in development and has not received FDA clearance for the US market. Accuracy specifications will be updated once clinical trial results are publicly available.
What Does the Biolinq Shine Cost?
With insurance, the Biolinq Shine costs N/A — not yet commercially available. Without insurance, the price is N/A — not yet commercially available. The Biolinq Shine is not currently covered by Medicare.
The annual cost of the Biolinq Shine depends on sensor replacement frequency. With a 7-day sensor life, users need approximately 53 sensors per year. The shorter sensor life means more frequent replacements, which increases annual costs compared to 14-day and 15-day sensors.
For a complete breakdown of CGM costs across all devices, including manufacturer discount programs and patient assistance options, see our comprehensive CGM cost guide.
Sensor Wear Time: 7 Days
The Biolinq Shine sensor lasts 7 days before requiring replacement. The 7-day wear time means approximately 53 sensor changes per year. This is shorter than the 14 to 15-day sensors from Abbott and the 15-day Dexcom G7 variant, resulting in more frequent insertions and potentially higher annual sensor costs.
The 0-minute warmup is the fastest in the CGM market, minimizing the data gap between sensor changes. This is particularly valuable for patients who depend on continuous glucose data for insulin dosing or overnight monitoring.
App and Data Sharing
The Biolinq Shine pairs with a dedicated smartphone app that displays real-time glucose values, trend arrows, and historical data. Data sharing with caregivers or healthcare providers is not available on this device. This device does not include real-time glucose alerts or alarms — it provides glucose data for awareness and trend tracking only.
Pros and Cons
Pros
- No needle insertion — uses novel on-skin biosensor technology
- Painless application with no subcutaneous filament
- Potential for very thin, discreet form factor
- May expand CGM adoption among needle-averse populations
- Backed by significant venture capital funding
Cons
- Still in clinical trials — not commercially available
- No published MARD data from pivotal trials
- No FDA clearance timeline confirmed
- Unproven long-term accuracy and reliability
- Pricing not yet announced
- 7-day projected wear time is shorter than competitors
Who Should Use the Biolinq Shine?
The Biolinq Shine is designed for adults 18 and older who want continuous glucose monitoring without a prescription. This includes people with prediabetes who want to detect insulin resistance early, wellness-focused individuals optimizing their metabolic health, athletes tracking glucose during training, and anyone curious about how food, exercise, and sleep affect blood sugar. The Biolinq Shine is not appropriate for insulin-dependent diabetes management because it lacks the real-time alerts, pump integration, and clinical-grade features required for safe insulin dosing.
How Does the Biolinq Shine Compare?
See how the Biolinq Shine stacks up against competing continuous glucose monitors in our head-to-head comparison guides. Each comparison evaluates accuracy, wear time, cost, features, and which device is better for specific use cases.
Biolinq Shine
by Emerging Brands